We are analyzing https://link.springer.com/article/10.1007/s11060-011-0749-4.

Title:
Glioblastoma survival in the United States before and during the temozolomide era | Journal of Neuro-Oncology
Description:
The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benefit extends to patients older than those enrolled in the trial. Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed to compare survival of adult glioblastoma patients diagnosed from 2000–2003 to patients diagnosed from 2005–2008, in order to evaluate pre-temozolomide and post-temozolomide periods. The Kaplan–Meier method and Cox proportional hazards models were used. 6,673 patients with glioblastoma diagnosed from 2000–2003 and 7,259 patients diagnosed from 2005–2008 were identified. Median survival times of all patients diagnosed in the 2000–2003 and 2005–2008 periods were 8.1 and 9.7 months, respectively. Amongst patients treated with surgery and a radiation-containing regimen, median survival was 12.0 months in 2000–2003 and 14.2 months in 2005–2008. In the temozolomide era, median survival times ranged from a high of 31.9 months in patients age 20–29 to a low of 5.6 months in patients age 80 and older. The survival of patients with newly diagnosed glioblastoma improved from 2000–2003 to 2005–2008, likely due to temozolomide use. However, median survival time after glioblastoma diagnosis in the SEER population remains well under one year, largely driven by poor prognosis in elderly patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, glioblastoma, survival, patients, pubmed, google, scholar, cancer, temozolomide, diagnosed, clinical, research, cas, surveillance, program, brain, privacy, cookies, content, data, journal, united, states, end, results, seer, months, access, stupp, van, analysis, publish, search, study, johnson, epidemiology, median, mason, bent, weller, taphoorn, cairncross, mirimanoff, radiotherapy, oncol, trials, clin, author, information, log,

Topics {✒️}

org/2011-npcr-seer/web-0407-report-3-3-2011 month download article/chapter brain cancer incidence national cancer institute seer population remains �good study patient recurrent glioblastoma multiforme clinical research associate influenced patient survival survival benefit extends poor prognosis brain tumors privacy choices/manage cookies seerstat database full article pdf cancer statistics branch median survival times phase iii studies physicians’ survival predictions neuro-oncology aims primary brain eortc-ncic trial routine clinical practice evaluate pre-temozolomide supratentorial glioblastoma resection van groeningen cj median survival time european economic area kaplan–meier method related subjects academic medical center mgmt gene silencing county attributes—total clinical article surveillance research program conditions privacy policy cbtrus statistical report herndon je 2nd johnson & brian patrick article journal post-temozolomide periods accepting optional cookies usage analysis check access single-institution experience instant access journal finder publish glioblastoma survival main content log article johnson

Questions {❓}

Joseph G, Dohan D (2009) Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Glioblastoma survival in the United States before and during the temozolomide era
         description:The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benefit extends to patients older than those enrolled in the trial. Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed to compare survival of adult glioblastoma patients diagnosed from 2000–2003 to patients diagnosed from 2005–2008, in order to evaluate pre-temozolomide and post-temozolomide periods. The Kaplan–Meier method and Cox proportional hazards models were used. 6,673 patients with glioblastoma diagnosed from 2000–2003 and 7,259 patients diagnosed from 2005–2008 were identified. Median survival times of all patients diagnosed in the 2000–2003 and 2005–2008 periods were 8.1 and 9.7 months, respectively. Amongst patients treated with surgery and a radiation-containing regimen, median survival was 12.0 months in 2000–2003 and 14.2 months in 2005–2008. In the temozolomide era, median survival times ranged from a high of 31.9 months in patients age 20–29 to a low of 5.6 months in patients age 80 and older. The survival of patients with newly diagnosed glioblastoma improved from 2000–2003 to 2005–2008, likely due to temozolomide use. However, median survival time after glioblastoma diagnosis in the SEER population remains well under one year, largely driven by poor prognosis in elderly patients.
         datePublished:2011-11-02T00:00:00Z
         dateModified:2011-11-02T00:00:00Z
         pageStart:359
         pageEnd:364
         sameAs:https://doi.org/10.1007/s11060-011-0749-4
         keywords:
            Glioblastoma
            Survival
            Temozolomide
            Prognosis
            Elderly
            Oncology
            Neurology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-011-0749-4/MediaObjects/11060_2011_749_Fig1_HTML.gif
         isPartOf:
            name:Journal of Neuro-Oncology
            issn:
               1573-7373
               0167-594X
            volumeNumber:107
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Derek R. Johnson
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Department of Neurology, Mayo Clinic, Rochester, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Brian Patrick O’Neill
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Department of Neurology, Mayo Clinic, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Glioblastoma survival in the United States before and during the temozolomide era
      description:The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benefit extends to patients older than those enrolled in the trial. Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed to compare survival of adult glioblastoma patients diagnosed from 2000–2003 to patients diagnosed from 2005–2008, in order to evaluate pre-temozolomide and post-temozolomide periods. The Kaplan–Meier method and Cox proportional hazards models were used. 6,673 patients with glioblastoma diagnosed from 2000–2003 and 7,259 patients diagnosed from 2005–2008 were identified. Median survival times of all patients diagnosed in the 2000–2003 and 2005–2008 periods were 8.1 and 9.7 months, respectively. Amongst patients treated with surgery and a radiation-containing regimen, median survival was 12.0 months in 2000–2003 and 14.2 months in 2005–2008. In the temozolomide era, median survival times ranged from a high of 31.9 months in patients age 20–29 to a low of 5.6 months in patients age 80 and older. The survival of patients with newly diagnosed glioblastoma improved from 2000–2003 to 2005–2008, likely due to temozolomide use. However, median survival time after glioblastoma diagnosis in the SEER population remains well under one year, largely driven by poor prognosis in elderly patients.
      datePublished:2011-11-02T00:00:00Z
      dateModified:2011-11-02T00:00:00Z
      pageStart:359
      pageEnd:364
      sameAs:https://doi.org/10.1007/s11060-011-0749-4
      keywords:
         Glioblastoma
         Survival
         Temozolomide
         Prognosis
         Elderly
         Oncology
         Neurology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-011-0749-4/MediaObjects/11060_2011_749_Fig1_HTML.gif
      isPartOf:
         name:Journal of Neuro-Oncology
         issn:
            1573-7373
            0167-594X
         volumeNumber:107
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Derek R. Johnson
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Department of Neurology, Mayo Clinic, Rochester, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Brian Patrick O’Neill
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Department of Neurology, Mayo Clinic, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Neuro-Oncology
      issn:
         1573-7373
         0167-594X
      volumeNumber:107
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic
      address:
         name:Department of Neurology, Mayo Clinic, Rochester, USA
         type:PostalAddress
      name:Mayo Clinic
      address:
         name:Department of Neurology, Mayo Clinic, Rochester, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Derek R. Johnson
      affiliation:
            name:Mayo Clinic
            address:
               name:Department of Neurology, Mayo Clinic, Rochester, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Brian Patrick O’Neill
      affiliation:
            name:Mayo Clinic
            address:
               name:Department of Neurology, Mayo Clinic, Rochester, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neurology, Mayo Clinic, Rochester, USA
      name:Department of Neurology, Mayo Clinic, Rochester, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(75)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.11s.

LINK . SPRINGER . COM {}